EMAS clinical guide: Selective estrogen receptor modulators for postmenopausal osteoporosis

Maturitas

Volumn 71, Issue 2, 2012, Pages 194-198

  Palacios, Santiago ^a   Brincat, Mark ^b   Erel, C Tamer ^c   Gambacciani, Marco ^d   Lambrinoudaki, Irene ^e   Moen, Mette H ^f,g   Schenck Gustafsson, Karin ^h   Tremollieres, Florence ⁱ   Vujovic, Svetlana ^j   Rees, Margaret ^k   Rozenberg, Serge ^l  

^a Palacios Institute of Woman's Health   (Spain)

^b MATER DEI HOSPITAL   (Malta)

^c ISTANBUL UNIVERSITY   (Turkey)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF ATHENS   (Greece)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ Paul Sabatier University   (France)

^j UNIVERSITY OF BELGRADE   (Serbia)

^k JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^l SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Bazedoxifene; Lasofoxifene; Postmenopausal osteoporosis; Raloxifene; Selective estrogen receptor modulators; Tamoxifen

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; LASOFOXIFENE; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CATARACT; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HOT FLUSH; HUMAN; LEG CRAMP; LUNG EMBOLISM; OVARY CYST; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RETINA VEIN OCCLUSION; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES;

EID: 84855812729     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.11.010     Document Type: Article

References (37)

1. A. Leboime, C.B. Confavreux, N. Mehsen, J. Paccou, C. David, and C. Roux Osteoporosis and mortality Joint Bone Spine 77 December (Suppl 2) 2010 S107 S112
2. World Health Organization. http://www.who.int/nutrition/topics/5- population-nutrient/en/index25.html [accessed 08.11.11].
3. O. Johnell, and J.A. Kanis An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 12 2006 1726 1733 (Pubitemid 44607392)
4. J.A. Kanis, and O. Johnell Requirements for DXA for the management of osteoporosis in Europe Osteoporos Int 16 2005 229 238 (Pubitemid 40379422)
5. M. Rees, J. Stevenson, S. Hope, S. Palacios, and S. Rozenberg Management of the menopause 5th ed. 2009 Royal Society of Medicine Press
6. E.M. Lewiecki Treatment of osteoporosis with denosumab Maturitas 66 June (2) 2010 182 186
7. S. Rozenberg, and S. Dutton Bisphosphonates and oesophageal cancer risk: where are we now? Maturitas 68 February (2) 2011 106 108
8. J.H. Pickar, T. MacNeil, and K. Ohleth SERMs: progress and future perspectives Maturitas 67 October (2) 2010 129 138
9. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388 (Pubitemid 28439961)
10. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 97 2005 1652 1662 (Pubitemid 41672231)
11. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467
12. H. Ding, and T.S. Field Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen? Cancer Treat Rev 33 October (6) 2007 506 513 (Pubitemid 47355337)
13. M. Rabaglio, Z. Sun, and K.N. Price Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Ann Oncol 20 September (9) 2009 1489 1498
14. E. Seeman, G.G. Crans, A. Diez-Perez, K.V. Pinette, and P.D. Delmas Anti-vertebral fracture efficacy of raloxifene: a meta-analysis Osteoporos Int 17 February (2) 2006 313 316 (Pubitemid 43053597)
15. E.S. Siris, S.T. Harris, and R. Eastell Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study J Bone Miner Res 20 September (9) 2005 1514 1524 (Pubitemid 41243540)
16. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 23 2006 2727 2741
17. V.G. Vogel, J.P. Costantino, and D.L. Wickerham National Surgical Adjuvant Breast and Bowel Project, Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer Cancer Prev Res (Phila) 3 June (6) 2010 696 706
18. E. Barrett-Connor, L. Mosca, and P. Collins Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 2006 125 137 (Pubitemid 44050394)
19. P. Collins, L. Mosca, and M.J. Geiger Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors Circulation 119 7 2009 922 930
20. G.C. Davies, W.J. Huster, Y. Lu, L. Plouffe, and M. Lakshmanan Adverse events reported by postmenopausal women in controlled trials with raloxifene Obstet Gynecol 93 1999 558 565 (Pubitemid 29147076)
21. S. Palacios, M.L. Farias, and H. Luebbert Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate Am J Obstet Gynecol 191 July (1) 2004 121 131 (Pubitemid 39077964)
22. P.D. Miller, A.A. Chines, and C. Christiansen Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 23 2008 525 535 (Pubitemid 351501893)
23. S.L. Silverman, C. Christiansen, and H.K. Genant Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial J Bone Miner Res 23 2008 1923 1934
24. S.L. Silverman, A.A. Chines, and D.L. Kendler Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study Osteoporos Int 2011 [Epub ahead of print]
25. Palacios S, Silverman S, Levira A, Pallay A, Kaufman J, Brown J, et al. Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study. Presented at: 13th International Menopause Society World Congress on Menopause, June 8-11, 2011. Rome, Italy [Abstract 973].
26. R.A. Lobo, J.V. Pinkerton, and M.L. Gass Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile Fertil Steril 92 September (3) 2009 1025 1038
27. R. Kagan, R.S. Williams, K. Pan, S. Mirkin, and J.H. Pickar A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women Menopause 17 March (2) 2010 281 289
28. R. Lindsay, J.C. Gallagher, R. Kagan, J.H. Pickar, and G. Constantine Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women Fertil Steril 92 September (3) 2009 1045 1052
29. C. Christiansen, C.H. Chesnut 3rd, and J.D. Adachi Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis BMC Musculoskelet Disord 11 2010 130
30. T.J. De Villiers, A.A. Chines, and S. Palacios Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial Osteoporos Int 22 February (2) 2011 567 576
31. R.L. Rosati, P. Da Silva Jardine, and K.O. Cameron Discovery and preclinical pharmacology of a novel, potent, non-steroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene J Med Chem 41 16 1998 2928 2931 (Pubitemid 28359926)
32. H.Z. Ke, V.M. Paralkar, and W.A. Grasser Effects of CP-336,156, a new, non-steroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models Endocrinology 139 April (4) 1998 2068 2076 (Pubitemid 28513870)
33. FABLYN® (lasofoxifene tartrate). 0.5 mg tablets, NDA22-242, Reproductive Health Drugs Advisory Committee Briefing Document. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-829 4381b1-02-Pfizer.pdf; 2008 [accessed on 25.02.11].
34. Fablyn® (lasofoxifene tartrate). Summary of product characteristics. Pfizer. Final Summary Minutes, Advisory Committee for Reproductive Health Drugs Meeting. Available from: http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008- 4381m1-final.pdf; 2008 [accessed on 25.03.11].
35. S.R. Cummings, K. Ensrud, and P.D. Delmas Lasofoxifene in postmenopausal women with osteoporosis N Engl J Med 362 8 2010 686 696
36. A.Z. LaCroix, T. Powles, and C.K. Osborne Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women J Natl Cancer Inst 102 22 2010 1706 1715
37. Final Summary Minutes, Advisory Committee for Reproductive Health Drugs Meeting. Available from: http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008- 4381m1-final.pdf; 2008 [accessed on 25.03.11].